DLin-KC2-DMA
- Product Name
- DLin-KC2-DMA
- CAS No.
- 1190197-97-7
- Chemical Name
- DLin-KC2-DMA
- Synonyms
- KC2;DLin-KC2-DMA;DLin-KC-2-DMA,inhibit,Inhibitor,DLin KC2 DMA,DLinKC2DMA;1,3-Dioxolane-4-ethanamine, N,N-dimethyl-2,2-di-(9Z,12Z)-9,12-octadecadien-1-yl-;2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-N,N-dimethylethanamine;2-(2,2-Di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethanamine
- CBNumber
- CB93361767
- Molecular Formula
- C43H79NO2
- Formula Weight
- 642.09
- MOL File
- 1190197-97-7.mol
DLin-KC2-DMA Property
- Boiling point:
- 668.1±40.0 °C(Predicted)
- Density
- 0.885±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C,unstable in solution, ready to use.
- solubility
- Soluble in Ethanol, DMSO, DMF
- pka
- 9.32±0.28(Predicted)
- form
- Liquid
- color
- Colorless to light yellow
- InChIKey
- LRFJOIPOPUJUMI-MNMREVDWSA-N
- SMILES
- O1CC(CCN(C)C)OC1(CCCCCCCCC=CCC=CCCCCC)CCCCCCCC/C=C\C/C=C\CCCCC
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H225Highly Flammable liquid and vapour
H319Causes serious eye irritation
- Precautionary statements
-
P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P233Keep container tightly closed.
P240Ground/bond container and receiving equipment.
P241Use explosion-proof electrical/ventilating/lighting/…/equipment.
P242Use only non-sparking tools.
P243Take precautionary measures against static discharge.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P337+P313IF eye irritation persists: Get medical advice/attention.
P370+P378In case of fire: Use … for extinction.
P403+P235Store in a well-ventilated place. Keep cool.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- orb573022
- Product name
- DLin-KC2-DMA
- Purity
- >98%
- Packaging
- 25mg
- Price
- $838.1
- Updated
- 2021/12/16
- Product number
- orb573022
- Product name
- DLin-KC2-DMA
- Purity
- >98%
- Packaging
- 100mg
- Price
- $1504.5
- Updated
- 2021/12/16
- Product number
- orb573022
- Product name
- DLin-KC2-DMA
- Purity
- >98%
- Packaging
- 250mg
- Price
- $2691.1
- Updated
- 2021/12/16
- Product number
- DC12381
- Product name
- DLin-KC2-DMA
- Purity
- >98%
- Packaging
- 25mg
- Price
- $550
- Updated
- 2021/12/16
- Product number
- DC12381
- Product name
- DLin-KC2-DMA
- Purity
- >98%
- Packaging
- 100mg
- Price
- $1000
- Updated
- 2021/12/16
DLin-KC2-DMA Chemical Properties,Usage,Production
Description
DLin-KC2-DMA is a useful ionizable lipid for siRNA delivery. It was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates.
Uses
DLin-KC2-DMA, also known as KC2 (2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane) is an optimized ionizable cationic lipid (ICL) with a reported apparent pKa of 6.7. This pKa ensures an efficient encapsulation of nucleic acid polymers at low pH, a nearly neutral surface charge for the LNPs in the circulation at physiological pH, and a high positive surface charge at endosomal pH. More recently, it was determined that LNPs containing KC2 generated liposomal structures when the KC2 is protonated at pH 4, while forming electron-dense structures at pH 7.4. It is an ionizable cationic lipid that has been used to form lipid nanoparticles (LNPs) encapsulating siRNA or plasmid DNA for use in vitro and in vivo. LNPs containing DLin-KC2-DMA selectively accumulate in mice's liver after intravenous or intramuscular administration or localize to the retinal pigment epithelium and Müller glia after subretinal administration. DLin-KC2-DMA-containing LNPs encapsulating siRNA targeting F7 mRNA, which encodes Factor VII, reduce serum Factor VII levels in mice. Intravenous administration of DLin-KC2-DMA-containing LNPs encapsulating siRNA targeting AR mRNA, which encodes the androgen receptor, decreases serum prostate-specific antigen (PSA) and tumour androgen receptor levels in an LNCaP prostate cancer mouse xenograft model[1].
References
[1] Ramezanpour, M. et al. “Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function?.” Nanoscale 30 (2019): 14141–14146.
DLin-KC2-DMA Preparation Products And Raw materials
Raw materials
Preparation Products
DLin-KC2-DMA Suppliers
- Tel
- 021-QQ:65489617 15618227136
- Fax
- 21-5161 9052
- Sales@ATKchemical.com
- Country
- China
- ProdList
- 7290
- Advantage
- 58
- Tel
- +86-02787215551 +86-19945035818
- Fax
- 027-87215551
- 2936752263@qq.com
- Country
- China
- ProdList
- 7977
- Advantage
- 58
- Tel
- +86-13301875428
- sales@changyuhe.com
- Country
- China
- ProdList
- 305
- Advantage
- 58
- Tel
- 63313187 15358055255
- Fax
- QQ:63313187
- 63313187@qq.com
- Country
- China
- ProdList
- 1986
- Advantage
- 58
- Tel
- 19938173342 19181793067
- 1486288711@qq.com
- Country
- China
- ProdList
- 170
- Advantage
- 58
- Tel
- +86-0731-85567275 18932438858
- Fax
- QQ:3554193828
- sales05@chemfish.com
- Country
- China
- ProdList
- 8301
- Advantage
- 58
- Tel
- 028-81700200 18116577057
- Fax
- 028-81705658
- 3003855609@qq.com
- Country
- China
- ProdList
- 7887
- Advantage
- 56
- Tel
- 021-52996696,15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4566
- Advantage
- 55
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8012
- Advantage
- 62
- Tel
- 21-31433387 15618786686
- Fax
- QQ:1369748377
- sales@rechemscience.com
- Country
- China
- ProdList
- 2991
- Advantage
- 58
View Lastest Price from DLin-KC2-DMA manufacturers
- Product
- DLIN-KC2-DMA 1190197-97-7
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 99%HPLC
- Supply Ability
- 100KG
- Release date
- 2020-02-01